I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am a Healthcare Professional outside the US and UK Read more
I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

I am not a Healthcare Professional and I am outside the US and the UK Read more
Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.125

Impact of ErbB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SqCC of the lung

Glenwood D. Goss, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Salih Guclu, Dolores Isla, Joo Min Young, Alessandro Morabito, Andrea Ardizzoni, Shirish M. Gadgeel, Neil Gibson, Nicole Krämer, Flavio Solca, Agnieszka Cseh, Eva Ehrnrooth, Jean-Charles Soria

1200.125 LL8 ERB WCLC 2017 Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, et al. Lancet Oncol 2015;16(8):897–907

New developments in the treatment of advanced squamous cell lung cancer: focus on Afatinib

Hirsh V. Onco Targets Ther. 2017 May 11;10:2513-2526

Second-line afatinib for advanced  squamous cell carcinoma of the lung:  analysis of afatinib long-term responders  in the Phase III LUX-Lung 8 trial

Goss G, et al. WCLC 2017: OA23.03

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Felip E, et al. Clinical Lung Cancer, In press

Further information: PFS and OS curves

Goss GD, et al.WCLC 2017

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2017

Find information on afatinib and nintedanib's clinical data and Boehringer Ingelheim's activities at WCLC 2017